Section 01
What it's used for
FDA-approved for labor (Pitocin)
Synthetic oxytocin, sold as Pitocin, is FDA-approved and widely used to start or strengthen labor. It is one of the most commonly given medications in obstetrics, used in about 50 percent of births in the United States.
▸Clinical wording
Synthetic oxytocin (Pitocin) is FDA-approved and widely used for labor induction and augmentation. It is one of the most commonly administered medications in obstetrics, used in approximately 50% of US births.
Preventing bleeding after birth
Oxytocin is the first-choice treatment for preventing and treating heavy bleeding after childbirth, by making the uterus contract. The World Health Organization lists it as an essential medicine for exactly this use.
▸Clinical wording
Oxytocin is the first-line agent for prevention and treatment of postpartum hemorrhage through uterine contraction. WHO includes it on the List of Essential Medicines for this indication.
Social skills research in autism
Research on oxytocin given as a nasal spray in people with autism spectrum disorder shows improvements in reading social cues, eye contact, recognizing emotions, and social give-and-take. Trials show mixed, promising results.
▸Clinical wording
Intranasal oxytocin research shows improvements in social cognition, eye contact, emotion recognition, and social reciprocity in individuals with ASD. Multiple Phase 2/3 clinical trials have been conducted with mixed but promising results.
Mixed results for anxiety and PTSD
In a small trial (n=25) adding oxytocin to exposure therapy for social anxiety, it improved self-perception but not overall symptoms versus placebo. A 2025 trial (n=124) found it impaired, rather than helped, fear-extinction learning.
▸Clinical wording
In a small randomized trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder (n=25), oxytocin improved self-perception during exposure but did not produce a greater reduction in overall symptom severity than placebo. A 2025 human trial (n=124) found that oxytocin impaired, rather than enhanced, fear extinction learning. A separate small trial (n=35) reported reduced provoked symptoms in women with PTSD, but a Cochrane review concludes that evidence for oxytocin in PTSD prevention remains inconclusive.
Depression research
Research on oxytocin in depression shows improvements in sensitivity to social reward, emotional processing, and how people relate to others. It may be especially relevant for depression marked by loss of pleasure and social withdrawal.
▸Clinical wording
Oxytocin research in depression shows improvements in social reward sensitivity, emotional processing, and interpersonal function. Particularly relevant for depression with prominent anhedonia and social withdrawal.
Pain relief: evidence lacking
A review of three randomized trials (n=95) found oxytocin given from outside the body did not significantly reduce pain versus placebo overall. Evidence for low back pain, migraine, and fibromyalgia remains unestablished.
▸Clinical wording
A systematic review and meta-analysis of three randomized trials (n=95) found that exogenous oxytocin did not significantly reduce pain intensity compared with placebo overall. Narrative evidence for chronic low back pain and migraine was described as encouraging but not established, and the proposed benefit in fibromyalgia rests on a pathophysiology hypothesis rather than demonstrated analgesic efficacy in trials. Robust human-trial evidence for oxytocin as an analgesic in these chronic pain conditions is currently lacking.
Addiction research
In preclinical animal models, oxytocin reduced stress-triggered drug craving and self-administration. Clinical trials in people are exploring it as an add-on treatment for alcohol, opioid, and cocaine addiction.
▸Clinical wording
Oxytocin reduces stress-induced drug craving and self-administration in preclinical models. Clinical trials explore its potential as an adjunct in alcohol, opioid, and cocaine addiction treatment.
Section 02
Mechanism of Action
How the signal enters a cell
- Oxytocin binds its own receptor, found in womb muscle, milk-ejecting breast cells and widely across the brain.
- Brain sites include the amygdala, hippocampus, nucleus accumbens and prefrontal cortex.
- Binding sets off an internal cascade that raises calcium inside the cell and activates an enzyme (PKC).
▸Clinical wording
Oxytocin Receptor Signaling
Oxytocin binds to the oxytocin receptor (OXTR), a Gq/11-coupled GPCR expressed in uterine myometrium, mammary myoepithelial cells, and widely throughout the brain (amygdala, hippocampus, nucleus accumbens, prefrontal cortex). Gq activation triggers PLC-IP3/DAG signaling, increasing intracellular calcium and activating PKC.
Making the womb muscle squeeze
- In womb muscle cells the calcium rise activates an enzyme that drives the contraction machinery.
- Protein filaments then cycle against each other, producing smooth muscle contraction.
- Receptor numbers in the uterus rise 100 to 200 fold during pregnancy, leaving the full-term womb extremely sensitive.
▸Clinical wording
Uterine Contraction
In myometrial cells, oxytocin-induced calcium elevation activates myosin light chain kinase (MLCK), leading to actin-myosin cross-bridge cycling and smooth muscle contraction. Oxytocin receptor density in the uterus increases 100-200 fold during pregnancy, making the term uterus exquisitely sensitive to oxytocin.
Less fear, more social reward
- Receptor activation in the amygdala lowers fear responses and the perception of threat.
- Receptor activation in the reward centre strengthens the reward signal tied to social interaction.
- The source describes this pairing as the basis of bonding, trust and attachment.
▸Clinical wording
Social Bonding and Trust
In the brain, OXTR activation in the amygdala reduces fear responses and threat perception, while OXTR activation in the nucleus accumbens enhances reward signaling associated with social interactions. This dual mechanism — reduced social anxiety plus enhanced social reward — underlies oxytocin's promotion of bonding, trust, and attachment.
Turning down the stress axis
- Oxytocin dampens the main stress hormone axis by inhibiting neurons that release its trigger hormone.
- The stress hormones cortisol and its pituitary trigger (ACTH) then respond less to stressors.
- The source describes anxiety-reducing and stress-buffering effects, particularly in social settings.
▸Clinical wording
Stress Response Modulation
Oxytocin attenuates the HPA (hypothalamic-pituitary-adrenal) stress axis by inhibiting CRH (corticotropin-releasing hormone) neurons in the paraventricular nucleus. This reduces cortisol and ACTH responses to stressors, producing anxiolytic and stress-buffering effects — particularly in social contexts.
Damping pain signals
- Oxytocin is described as having pain-relieving properties acting through two separate routes.
- One route is receptor activation on sensory nerves outside the brain and spinal cord.
- The other is action on pain circuits in the spinal cord and midbrain.
▸Clinical wording
Pain Modulation
Oxytocin has analgesic properties, mediated through both peripheral OXTR activation on sensory neurons and central modulation of pain circuits in the spinal cord and periaqueductal gray.
Section 03
Biological Pathways
- Gq/PLC/IP3/Calcium Contractile PathwayOXTR→Gq→PLC→IP3→ER calcium release→calmodulin→MLCK→myosin phosphorylation, the primary driver of uterine contraction and the milk ejection reflex.
- Dopamine/Reward Social PathwayIn the VTA and nucleus accumbens, oxytocin boosts dopamine release during social interaction, reinforcing bonding through reward activation and a positive feedback loop with social contact.
- GABA/Amygdala AnxiolysisOxytocin strengthens GABAergic inhibition in the central amygdala, dampening fear conditioning and anxiety and easing social threat perception.
- CRH/HPA Stress SuppressionOxytocin neurons in the PVN inhibit CRH-producing neurons, curbing HPA axis activation and lowering cortisol, ACTH, and autonomic stress responses.
Section 04
Dosage Information
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (disulfide: Cys1-Cys6)| Route / system | Context | Range studied | Limitation |
|---|---|---|---|
| Intravenous — labour induction | FDA label (Pitocin), induction or stimulation of labour | 10 units in 1000 mL, from 0.5–1 mU/min, raised 1–2 mU/min every 30–60 minutes; over 9–10 mU/min is rarely needed. Not dosed by weight. | The approved use, but not a fixed dose: the rate follows the contractions and continuous fetal heart monitoring, and none of it works outside a delivery room. |
| Intravenous / intramuscular — postpartum | FDA label, third stage of labour and postpartum bleeding | 10 units into muscle after the placenta, or 10–40 units in the running drip at 10–20 mU/min. No more than 30 units per 12 hours. | The cap has a reason: oxytocin makes the body hold water, and 24-hour drips have caused water poisoning, seizures, coma and maternal death. |
| Intranasal — single-dose experiments | Laboratory studies of trust and social behaviour | 24 IU in one dose — about 40 µg of peptide, at 1.68 µg per IU. Against 8 IU in the same 17 people, the effect showed at 8 IU, not 24. | 24 IU came from earlier studies, not from pharmacology, and the comparison points away from higher doses. One dose in a lab task is not a course. |
| Intranasal — repeat-dose trials | Phase 2 autism and schizophrenia trials, weeks to months | Autism: 277 children, 24 weeks, 8 IU per dose rising toward 48 IU a day. Schizophrenia: 24–80 IU a day, average 47.6 IU, 3–16 weeks. | Both came out negative: social functioning improved at none of these amounts. These are the doses that failed, not a target range. |
| Intranasal — self-administration | Pharmacy-mixed nasal sprays, outside any trial | Sprays of 100 IU/mL: about 10 IU per dose from one 0.1 mL puff per nostril, up to twice a day, adjusted in 5–10 IU steps. | Practice, not a finding: the steps come from a pharmacy's own instructions, and no trial has tested daily nasal oxytocin in healthy adults for these effects. |
Results
Syringe Fill Level (100u syringe)
Set positive values for: Recommended dose per kg.
Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.
Section 05
Protocols
No protocols featuring this peptide yet. Browse All Protocols
Section 06
Stability & Storage
Lyophilised powder
Research-grade oxytocin powder is kept at −20 °C; the disulfide bond between Cys1 and Cys6 is essential for activity and sensitive to reducing conditions, so it is reconstituted with sterile water or saline rather than bacteriostatic water containing benzyl alcohol. The commercial injectable solution (10 IU/mL) is stored at 20–25 °C or 2–8 °C with a 2–3 year shelf life, while the 40 IU/mL nasal spray is kept at 2–8 °C.
After reconstitution
Once reconstituted, the powder solution is stored at 2–8 °C and used within 14 days; oxytocin is sensitive to heat, light, and alkaline pH. The nasal spray follows a similar pattern: once opened, it is kept at 2–8 °C and used within 3 months, as the nasal formulation is more temperature-sensitive than the injectable form.
Section 07
Side Effects & Precautions
Reported effects differ sharply by route: intravenous oxytocin carries obstetric and cardiovascular risks, while intranasal use causes milder local effects. Its effect on social behavior is also more complex than simple trust-building.
Intravenous Administration
- Uterine hyperstimulation (excessive contractions) is the primary risk in labor and obstetric use, and can cause fetal distress, uterine rupture, or placental abruption.
- Because of this risk, IV use in labor involves careful dose titration and fetal monitoring.
- Prolonged high-dose IV infusion can cause water intoxication and low blood sodium (hyponatremia), from oxytocin's antidiuretic activity.
- Bolus IV doses can cause transient low blood pressure and a fast heart rate, from oxytocin's vessel-relaxing effect; these effects are dose-dependent.
Intranasal Administration
Nasal irritation and a runny nose (rhinorrhea) are the most common side effects. Mild headache (10-15%) and drowsiness are also reported, and nausea can occur at higher doses.
Potential Negative Social Effects
Emerging research suggests oxytocin can increase favoritism toward one's own group while increasing hostility toward outside groups. Its prosocial effects depend on context and may amplify existing social biases rather than producing universal trust.
Long-Term Use Remains Understudied
Long-term safety data for chronic intranasal use are limited. Open concerns include possible receptor desensitization with chronic use and unknown effects on social behavior from prolonged use of exogenous oxytocin.
Section 08
Regulatory Status
Every other form and application it is popularly known for — intranasal, psychiatric, bonding-related — sits entirely outside that approval.
FDA / United States
Approved by injection for obstetric use
As Pitocin, oxytocin is FDA-approved for inducing or reinforcing labor and for controlling postpartum hemorrhage, given by injection under medical supervision. It is on the WHO Model List of Essential Medicines, and comparable obstetric approvals exist at regulatory agencies worldwide.
Intranasal oxytocin
Not FDA-approved for any use
A prescription nasal spray (Syntocinon) is authorised in some countries to help with milk let-down, but no intranasal oxytocin product has FDA approval in the United States for that or any other purpose. Every study of intranasal oxytocin for autism, anxiety, PTSD, or social bonding remains investigational.
WADA
Not on the prohibited list
Oxytocin does not appear in any category of the WADA Prohibited List and carries no anti-doping restriction for competing athletes. It remains a prescription medicine in most countries but is not a controlled substance.
None of this extends to compounded or over-the-counter oxytocin products sold outside the approved Pitocin injection, which carry none of its quality or dosing oversight. Regulatory status differs between jurisdictions and changes over time; check the current documents of your own regulator before relying on any of this.
Section 09
Research Studies
- [1]The Oxytocin Receptor System: Structure, Function, and RegulationGimpl G, Fahrenholz F. · Physiological Reviews · 2001
- [2]The Oxytocin Receptor: From Intracellular Signaling to BehaviorJurek B, Neumann ID. · Physiological Reviews · 2018
- [3]Oxytocin: Its Mechanism of Action and Receptor Signalling in the MyometriumArrowsmith S, Wray S. · Journal of Neuroendocrinology · 2014
- [4]Oxytocin receptors in the human uterus during pregnancy and parturitionFuchs AR, Fuchs F, Husslein P, Soloff MS. · American Journal of Obstetrics and Gynecology · 1984
- [5]Oxytocin increases trust in humansKosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. · Nature · 2005
- [6]Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in HumansKirsch P, Esslinger C, Chen Q, et al. · The Journal of Neuroscience · 2005
- [7]Social reward requires coordinated activity of nucleus accumbens oxytocin and serotoninDolen G, Darvishzadeh A, Huang KW, Malenka RC. · Nature · 2013
- [8]Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviorsNeumann ID, Landgraf R. · Trends in Neurosciences · 2012
- [9]Oxytocin and Pain Perception: From Animal Models to Human ResearchBoll S, Almeida de Minas AC, Raftogianni A, Herpertz SC, Grinevich V. · Neuroscience · 2018
- [10]Intranasal Oxytocin: Myths and DelusionsLeng G, Ludwig M. · Biological Psychiatry · 2016
Section 10
Frequently Asked Questions
The idea took off after a 2005 study reported that oxytocin increased trust in a monetary game, and follow-up work described it reducing amygdala fear responses while enhancing reward signalling for social interaction. Later results are decidedly mixed: a 2025 trial in 124 people found oxytocin impaired rather than enhanced fear-extinction learning, autism trials show inconsistent effects, a Cochrane review calls the PTSD evidence inconclusive, and a 2016 review is titled, plainly, "Intranasal Oxytocin: Myths and Delusions."
For its approved use, labor induction, the IV infusion rate is titrated upward every 30-60 minutes based on the contraction response, which is the interval clinicians use to judge whether a rate is working. No study in its research record measured onset of effect for other routes, such as nasal spray used for social or emotional effects.
As synthetic Pitocin, it is FDA-approved specifically for use during labor at term, given by IV under continuous fetal monitoring because of real risks - uterine hyperstimulation and water intoxication with hyponatremia at high infused doses. That approval covers supervised obstetric administration only; no data in its research record address other routes or timing earlier in pregnancy.
By IV, the main risk is uterine hyperstimulation, which can cause fetal distress or uterine rupture, plus water intoxication with prolonged high-dose infusion. Intranasally, nasal irritation and runny nose are most common, with headache in 10-15% of users; bolus IV dosing can also cause transient low blood pressure and rapid heart rate, and some research suggests its social effects cut both ways, increasing favoritism toward one's own group alongside hostility toward outsiders.
Synthetic oxytocin (Pitocin) is FDA-approved and prescription-only for labor induction and postpartum hemorrhage, and is on the WHO Essential Medicines list for that use. Intranasal oxytocin is prescription-only in some countries for milk let-down, but its use for psychiatric or social-behavior purposes remains investigational and is not an approved indication anywhere; it is not a controlled substance and not on WADA's prohibited list.
It earned the name from its dual action in the brain: activating its receptor in the amygdala reduces fear and threat perception, while activating the same receptor in the nucleus accumbens boosts reward signalling tied to social interaction - a combination linked to bonding, trust and attachment. The label oversimplifies, though: newer research finds its prosocial effect is context-dependent and can amplify in-group favoritism and out-group hostility rather than produce trust universally.
The commercial injectable (10 IU/mL) can be kept at 20-25 °C or 2-8 °C with a 2-3 year shelf life, while the 40 IU/mL nasal spray is stored at 2-8 °C and used within 3 months once opened. Research-grade lyophilised powder is kept at -20 °C, and once reconstituted the solution is stored at 2-8 °C and used within 14 days, since oxytocin is sensitive to heat, light and alkaline pH.